We mapped all estrogen receptor and RNA polymerase II binding sites on a genome-wide scale, identifying the authentic cis binding sites and target genes, in breast cancer cells.

On both estrogen receptor α 47 and estrogen receptor β, 48 the conformation of the ligand-binding domain changes in different ways when estradiol, raloxifene, or genistein binds to it.

Other endocrine therapies target the receptor itself either preventing estrogen from binding to the ERα and degrading the ERα, thereby reducing the opportunity for estrogen stimulation.

The selective estrogen-receptor modulators, or SERMs, chemically diverse nonsteroid compounds, have tertiary structures that permit binding to the estrogen receptor. These compounds have either sel ...

The transcription start sites of the 58 genes in the gene set that identifies the Luminal-type subgroup were determined after which the presence of Estrogen Receptor binding sites was analyzed within ...

Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the ...

Estrogen has been shown to promote neuronal survival in such models of Parkinson’s, thought to be due to estrogen's ability to interfere with dopamine binding for reuptake at presynaptic sites.

Discover how high-speed AFM reveals estrogen receptor binding to DNA, enhancing understanding of gene regulation. Learn more about this breakthrough.

Because estrogen receptor binders can prevent cancer-causing compounds from binding to estrogen, they may be able to thwart the growth of cancerous tumors.

This type of breast cancer involves cancer cells that have estrogen receptors just like normal breast cells. When estrogen binds to receptor sites in cancer cells, it makes them grow.

The promise of new pharmaceutical treatments from a class of powerful plant compounds called isoflavonoids has remained unfulfilled because of problems biosynthesizing sufficient quantities of the ...